• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A Brief Discussion of Multi-Component Organic Solids: Key Emphasis on Co-Crystallization.多组分有机固体简述:重点聚焦于共结晶
Turk J Pharm Sci. 2022 Apr 29;19(2):220-231. doi: 10.4274/tjps.galenos.2020.78700.
2
Co-Crystallization: A Novel Technique to Improvise the Pharmaceutical Characteristics of API's.共晶:改善原料药药学性质的新技术。
Curr Drug Targets. 2023;24(11):870-888. doi: 10.2174/1389450124666230726152037.
3
Amino Acids as the Potential Co-Former for Co-Crystal Development: A Review.氨基酸作为共晶形成的潜在共形成物:综述。
Molecules. 2021 May 28;26(11):3279. doi: 10.3390/molecules26113279.
4
Pharmaceutical Co-Crystallization: Regulatory Aspects, Design, Characterization, and Applications.药物共结晶:监管方面、设计、表征及应用
Adv Pharm Bull. 2020 Jun;10(2):203-212. doi: 10.34172/apb.2020.024. Epub 2020 Feb 18.
5
Application of Cocrystallization Approach in Drug Development: Recent Patents Review.共结晶方法在药物研发中的应用:近期专利综述
Recent Pat Nanotechnol. 2018;12(2):143-154. doi: 10.2174/1872210512666180221153312.
6
Co-crystals: a novel approach to modify physicochemical properties of active pharmaceutical ingredients.共晶:一种改善活性药物成分物理化学性质的新方法。
Indian J Pharm Sci. 2009 Jul;71(4):359-70. doi: 10.4103/0250-474X.57283.
7
Recent Advancements in Pharmaceutical Cocrystals, Preparation Methods, and their Applications.药物共晶的最新进展、制备方法及其应用。
Curr Pharm Des. 2021;27(44):4477-4495. doi: 10.2174/1381612827666210415104411.
8
Pharmaceutical cocrystals, salts and multicomponent systems; intermolecular interactions and property based design.药物共晶、盐和多组分体系;分子间相互作用和基于性质的设计。
Adv Drug Deliv Rev. 2017 Aug 1;117:3-24. doi: 10.1016/j.addr.2017.03.003. Epub 2017 Mar 23.
9
An Examination of Water Vapor Sorption by Multicomponent Crystalline and Amorphous Solids and Its Effects on Their Solid-State Properties.多组分结晶和无定形固体对水蒸气的吸附及其对其固态性能的影响研究。
J Pharm Sci. 2019 Mar;108(3):1061-1080. doi: 10.1016/j.xphs.2018.10.038. Epub 2018 Nov 1.
10
Pharmaceutical cocrystallization techniques. Advances and challenges.药物共晶技术。进展与挑战。
Int J Pharm. 2018 Aug 25;547(1-2):404-420. doi: 10.1016/j.ijpharm.2018.06.024. Epub 2018 Jun 14.

本文引用的文献

1
Pharmaceutical cocrystals, salts and multicomponent systems; intermolecular interactions and property based design.药物共晶、盐和多组分体系;分子间相互作用和基于性质的设计。
Adv Drug Deliv Rev. 2017 Aug 1;117:3-24. doi: 10.1016/j.addr.2017.03.003. Epub 2017 Mar 23.
2
Engineering and manufacturing of pharmaceutical co-crystals: a review of solvent-free manufacturing technologies.药物共晶体的工程与制造:无溶剂制造技术综述
Chem Commun (Camb). 2016 Jul 7;52(57):8772-86. doi: 10.1039/c6cc01289b.
3
Improving the dissolution and bioavailability of 6-mercaptopurine via co-crystallization with isonicotinamide.通过与异烟酰胺共结晶提高6-巯基嘌呤的溶出度和生物利用度。
Bioorg Med Chem Lett. 2015 Mar 1;25(5):1036-9. doi: 10.1016/j.bmcl.2015.01.022. Epub 2015 Jan 17.
4
Eutectics as improved pharmaceutical materials: design, properties and characterization.低共熔物作为改良型药物材料:设计、性质与特征描述。
Chem Commun (Camb). 2014 Jan 28;50(8):906-23. doi: 10.1039/c3cc47521b.
5
Co-crystal screening of diclofenac.双氯芬酸共晶筛选。
Pharmaceutics. 2011 Aug 31;3(3):601-14. doi: 10.3390/pharmaceutics3030601.
6
Characteristics of indomethacin-saccharin (IMC-SAC) co-crystals prepared by an anti-solvent crystallization process.采用抗溶剂结晶法制备的吲哚美辛-糖精(IMC-SAC)共晶的特性。
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):854-61. doi: 10.1016/j.ejpb.2013.02.007. Epub 2013 Feb 27.
7
Establishment of cocrystal cocktail grinding method for rational screening of pharmaceutical cocrystals.建立共晶鸡尾酒研磨法以合理筛选药物共晶。
Int J Pharm. 2012 Nov 1;437(1-2):162-71. doi: 10.1016/j.ijpharm.2012.07.038. Epub 2012 Jul 31.
8
Physico-mechanical and stability evaluation of carbamazepine cocrystal with nicotinamide.卡马西平-烟酰胺共晶的物理力学和稳定性评价。
AAPS PharmSciTech. 2011 Jun;12(2):693-704. doi: 10.1208/s12249-011-9603-4. Epub 2011 May 20.
9
Physicochemical and mechanical properties of carbamazepine cocrystals with saccharin.卡马西平与糖精共晶的物理化学和力学性质。
Pharm Dev Technol. 2012 Jul-Aug;17(4):457-65. doi: 10.3109/10837450.2010.546412. Epub 2011 Jan 26.
10
Salt or co-crystal? Determination of protonation state by X-ray photoelectron spectroscopy (XPS).盐还是共晶?通过 X 射线光电子能谱 (XPS) 确定质子化状态。
J Pharm Sci. 2010 Nov;99(11):4453-7. doi: 10.1002/jps.22164.

多组分有机固体简述:重点聚焦于共结晶

A Brief Discussion of Multi-Component Organic Solids: Key Emphasis on Co-Crystallization.

作者信息

Dutt Braham, Choudhary Manjusha, Budhwar Vikas

机构信息

Maharishi Dayanand University, Department of Pharmaceutical Sciences, Haryana, India

Kurukshetra University, Institute of Pharmaceutical Sciences, Department of Pharmacy, Kurukshetra, India

出版信息

Turk J Pharm Sci. 2022 Apr 29;19(2):220-231. doi: 10.4274/tjps.galenos.2020.78700.

DOI:10.4274/tjps.galenos.2020.78700
PMID:35510356
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9083509/
Abstract

Co-crystallization (CCs) is a less studied phenomenon related to its applicability and reliability as it is directly related to the generation of newer multicomponent solids like co-crystals (CS), eutectic, salts or solid solutions . having improved physicochemical properties compared to their pure components. Further, the design and structural aspects of these multicomponent systems remain hindered compared to other techniques such as nanotechnology or solid dispersion. CC is a newer technique to modify the physicochemical as well as pharmaceutical characteristics of various drugs having issues like solubility, stability, . without altering or hindering their pharmacological activities. For drug delivery purpose, CC process has numerous advantages over nanotechnology and solid dispersion drug delivery techniques. CCs can modify the physicochemical properties of active pharmaceutical ingredients (API) have issues like sensitivity toward environmental hazards like temperature, moisture, or photostability issues. The availability of large numbers of conformers makes this technique favorable for the researchers in designing CS of newer and older. Although, solid dispersion and nanotechnology techniques are being utilized to a larger extent still there are some drawbacks of these techniques like stability, toxicological factors and protection from environmental factors need to be considered, while the CCs process drastically modifies the various pharmaceutical parameters without altering the pharmacological properties of API's. Salts, design of CS, their methods of preparation, and their application in various fields with special emphasis on their applicability in the pharmaceutical industry.

摘要

共结晶(CCs)是一种较少被研究的现象,涉及其适用性和可靠性,因为它与新型多组分固体如共晶体(CS)、低共熔物、盐或固溶体的产生直接相关,与它们的纯组分相比,这些多组分固体具有改善的物理化学性质。此外,与纳米技术或固体分散等其他技术相比,这些多组分体系的设计和结构方面仍然受到阻碍。共结晶是一种更新的技术,用于改变各种存在溶解度、稳定性等问题的药物的物理化学以及药学特性,而不改变或阻碍它们的药理活性。出于药物递送目的,共结晶过程相对于纳米技术和固体分散药物递送技术具有许多优势。共结晶可以改变活性药物成分(API)的物理化学性质,这些活性药物成分存在对温度、湿度等环境危害敏感或光稳定性问题。大量构象异构体的存在使得该技术有利于研究人员设计新的和旧的共晶体。尽管固体分散和纳米技术在很大程度上仍在被使用,但这些技术仍存在一些缺点,如稳定性、毒理学因素以及需要考虑免受环境因素影响,而共结晶过程在不改变API药理性质的情况下极大地改变了各种药学参数。盐、共晶体的设计、它们的制备方法以及它们在各个领域的应用,特别强调它们在制药工业中的适用性。